Psoriatic uveitis responding to adalimumab therapy

dc.contributor.authorErmertcan A.T.
dc.contributor.authorEmre S.
dc.contributor.authorÖztürk F.
dc.contributor.authorGençoǧlan G.
dc.contributor.authorGündüz K.
dc.date.accessioned2024-07-22T08:17:15Z
dc.date.available2024-07-22T08:17:15Z
dc.date.issued2014
dc.description.abstract[No abstract available]
dc.identifier.DOI-ID10.1111/ijd.12194
dc.identifier.issn00119059
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/17000
dc.language.isoEnglish
dc.publisherBlackwell Publishing Ltd
dc.subjectAdult
dc.subjectAnti-Inflammatory Agents
dc.subjectAntibodies, Monoclonal, Humanized
dc.subjectArthritis, Psoriatic
dc.subjectFemale
dc.subjectHumans
dc.subjectUveitis
dc.subjectadalimumab
dc.subjectalpha interferon
dc.subjectazathioprine
dc.subjectcyclosporin
dc.subjectsteroid
dc.subjectadult
dc.subjectbone radiography
dc.subjectbone scintiscanning
dc.subjectcase report
dc.subjecterythema
dc.subjecteye examination
dc.subjectfemale
dc.subjecthuman
dc.subjectletter
dc.subjectoptic neuritis
dc.subjectpruritus
dc.subjectpsoriasis
dc.subjectPsoriasis Severity Index
dc.subjectpsoriatic arthritis
dc.subjectpsoriatic uveitis
dc.subjectskin defect
dc.subjectskin examination
dc.subjectsteroid therapy
dc.subjectsystemic therapy
dc.subjecttopical treatment
dc.subjecttreatment response
dc.subjectuveitis
dc.subjectvisual acuity
dc.titlePsoriatic uveitis responding to adalimumab therapy
dc.typeLetter

Files